Payment overview · 2025
General Payments
$828.25
22 reported records · 14 companies
Healthcare provider profile · identity verified
Heather Leanne Smith, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · DAYTONA BEACH, FL · NPI 1225775729
Verified facts
What the public records show
CMS Open Payments records show Heather Leanne Smith, APRN received $828.25 in general payments during 2025 across 22 reported records.
Janssen Pharmaceuticals, Inc accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $253.83 | 30.6% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.52 | 18.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $118.06 | 14.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $50.32 | 6.1% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $50.11 | 6.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$43.16 | 5.2% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $43.13 | 5.2% | 2 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $25.10 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.19 | 2.2% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $17.62 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.60 | 1.9% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $14.84 | 1.8% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.48 | 1.8% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $14.29 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $828.25 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $253.83 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $149.52 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $118.06 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $50.32 | 2 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $50.11 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $50.11 | 1 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $43.13 | 2 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 120 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 113 | 44 |
| Tramadol Hcl | Tramadol Hcl | 84 | 22 |
| Eliquis | Apixaban | 83 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 82 | 29 |
| Trazodone Hcl | Trazodone Hcl | 81 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 30 |
| Pregabalin | Pregabalin | 66 | 15 |
| Gabapentin | Gabapentin | 65 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 21 |
| Lisinopril | Lisinopril | 54 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 53 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 49 | 21 |
| Lorazepam | Lorazepam | 45 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 41 | 19 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Omeprazole | Omeprazole | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 18 |
| Glipizide | Glipizide | 37 | suppressed |
| Metformin Hcl | Metformin Hcl | 37 | 14 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 15 |
| Prednisone | Prednisone | 25 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 15 |
| Alprazolam | Alprazolam | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Losartan Potassium | Losartan Potassium | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Famotidine | Famotidine | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methazolamide | Methazolamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $828.25 · 22 records | Janssen Pharmaceuticals, Inc | ACTIV.A.C., AQUACEL AG+ EXTRA, ELIQUIS, ENROUTE Transcarotid Stent, Fabhalta, GRAFIX PL, HAWKONE, IN.PACT ADMIRAL, Jornay PM, NURTEC ODT, OTEZLA, Onyda XR, PAXLOVID, Penumbra System, REPATHA, REXULTI, SPRAVATO, STRAVIX, Xelstrym | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error